Liothyronine sodium/Thiamazole

碘塞罗宁钠/甲巯咪唑

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLiothyronine sodium/Thiamazole
Drug Alias Namemethimazole + T3甲巯咪唑+碘塞罗宁钠liothyronine sodium+methimazole甲巯咪唑/碘塞罗宁钠methimazole + liothyronine sodium +[8] 
ClassificationSmall molecules
Mechanisms of ActionThyroid peroxidase inhibitorsThyroid hormone receptor beta-1 agonistsThyroid hormone receptor alpha agonists
TargetsThyroid peroxidaseThyroid hormone receptor betaThyroid hormone receptor alpha
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes MethimazoleLiothyronine sodium
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMusli Thyropeutics LtdAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesAbbott LaboratoriesMusli Thyropeutics Ltd
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A